Form 4: FMR LLC Reports Beam Therapeutics Stock Transactions

FMR LLC, a significant holder, disclosed transactions involving Beam Therapeutics Inc. (BEAM) common stock on June 25th and 26th, 2026.

Summary

• FMR LLC, acting as a 10% owner and director-related entity, reported the acquisition of 33,372 shares of Beam Therapeutics Inc. common stock on June 25, 2026, at a weighted average price of $35.12 per share.
• On June 26, 2026, FMR LLC acquired an additional 251,488 shares of Beam Therapeutics Inc. common stock at a weighted average price of $35.26 per share.
• Following these transactions, FMR LLC beneficially owns 1,106,071 shares indirectly through F-Prime Capital Partners Healthcare Fund V LP and 841,231 shares indirectly through FMR Capital, Inc.
• The filing also notes that shares are held by persons and entities whose shares are subject to reporting by FMR LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine stock transactions by a major shareholder and does not contain new strategic information or financial performance data.

Positives

• FMR LLC, a significant investor, increased its beneficial ownership of Beam Therapeutics Inc. common stock through multiple acquisitions.
• The transactions indicate continued investment and confidence from a major shareholder in Beam Therapeutics Inc.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the weighted average prices of multiple trades.
• The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into ownership changes. This filing indicates ongoing activity from a major investment entity in the biotechnology sector.

Stakeholder Impact

• Shareholders: Increased transparency into the holdings of a significant investor, FMR LLC, which may influence market perception.
• Management: The transactions by FMR LLC, a 10% owner and director-related entity, provide insight into their ongoing investment strategy.
• Regulators: Compliance with Section 16 of the Securities Exchange Act of 1934 is maintained through this filing.

Key Dates

Keywords

FMR LLC, Beam Therapeutics Inc., BEAM, Form 4, beneficial ownership, stock transaction, common stock, F-Prime Capital Partners Healthcare Fund V LP, FMR Capital, Inc.